SciSparc Ltd. announced that it received a notice of acceptance for its patent application for the Combinations of Cannabinoids and N-Acylethanolamines (the ?Patent?). The Patent aligns seamlessly with the Company?s core technologies design to enhance cannabinoids? safety by using low dosages of active components while maintaining their therapeutic benefits.

The Patent was granted by IP Australia, the government agency in Australia that administers intellectual property rights and legislation for patents. This Patent adds to the collection of patents previously granted in Europe, the United States and Japan, supporting the innovation of SciSparc?s technologies. The invention relates to compositions and methods for potentiating therapeutic effects and/or reducing the side-effects of selected cannabinoids initially discovered in the cannabis plant.

The Patent received protection on account of pharmaceutical compositions consisting of cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treated conditions of such pharmaceutical compositions.